Limits...
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.

Lee SH, Kim WS, Choi YD, Seo JW, Han JH, Kim MJ, Kim L, Lee GK, Lee CH, Oh MH, Kim GY, Sung SH, Lee KY, Chang SH, Rho MS, Kim HK, Jung SH, Jang SJ, Cardiopulmonary Pathology Study Group of Korean Society of Pathologis - J Pathol Transl Med (2015)

Bottom Line: We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy.EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Background: Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey.

Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.

Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.

No MeSH data available.


Related in: MedlinePlus

Frequency of mutations according to exons: 601 mutations in 1,753 specimens from patients with non-small cell lung cancer.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4696529&req=5

f3-jptm-2015-09-14: Frequency of mutations according to exons: 601 mutations in 1,753 specimens from patients with non-small cell lung cancer.

Mentions: In all, 601 cases of EGFR mutation (34.3%) were detected in NSCLC. Of these 601 patients, 560 (43.3%) had adenocarcinoma, 30 (8.6%) had squamous cell carcinoma, eight (11.6%) had NSCLC type undetermined, two (15.4%) had pleomorphic carcinoma, and one (8.3%) had large cell neuroendocrine carcinoma. In all, 389 never-smokers with adenocarcinoma (52.4%) had EGFR mutations. Of the 601 patients with NSCLC who had EGFR mutations, 30 (5%), 313 (52.1%), 31 (5.2%), and 205 (34.1%) had mutations in exons 18, 19, 20, and 21, respectively; in addition, 22 patients (3.7%) had double mutations (Fig. 3). Further, 13 patients (2.2%) had T790M mutation; of these, four patients had only the T790M mutation.


Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.

Lee SH, Kim WS, Choi YD, Seo JW, Han JH, Kim MJ, Kim L, Lee GK, Lee CH, Oh MH, Kim GY, Sung SH, Lee KY, Chang SH, Rho MS, Kim HK, Jung SH, Jang SJ, Cardiopulmonary Pathology Study Group of Korean Society of Pathologis - J Pathol Transl Med (2015)

Frequency of mutations according to exons: 601 mutations in 1,753 specimens from patients with non-small cell lung cancer.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4696529&req=5

f3-jptm-2015-09-14: Frequency of mutations according to exons: 601 mutations in 1,753 specimens from patients with non-small cell lung cancer.
Mentions: In all, 601 cases of EGFR mutation (34.3%) were detected in NSCLC. Of these 601 patients, 560 (43.3%) had adenocarcinoma, 30 (8.6%) had squamous cell carcinoma, eight (11.6%) had NSCLC type undetermined, two (15.4%) had pleomorphic carcinoma, and one (8.3%) had large cell neuroendocrine carcinoma. In all, 389 never-smokers with adenocarcinoma (52.4%) had EGFR mutations. Of the 601 patients with NSCLC who had EGFR mutations, 30 (5%), 313 (52.1%), 31 (5.2%), and 205 (34.1%) had mutations in exons 18, 19, 20, and 21, respectively; in addition, 22 patients (3.7%) had double mutations (Fig. 3). Further, 13 patients (2.2%) had T790M mutation; of these, four patients had only the T790M mutation.

Bottom Line: We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy.EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Background: Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey.

Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.

Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.

No MeSH data available.


Related in: MedlinePlus